REGN Regeneron Pharmaceuticals Earnings and EPS analysis

EPS in 2026 (TTM): $42.56

Last Report Period Date: Mar 31, 2026

As of June 2026, REGN's trailing twelve months (TTM) EPS stands at $42.56, according to the latest financial reports. In 2025, the company recorded an earnings per share (EPS) of $43.07, which represents an increase compared to its EPS of $40.9 in 2024. REGN reported an EPS of $6.99 for the quarterly report ending on Mar 31, 2026.

For 2025, Regeneron Pharmaceuticals's EPS was $43.07, an increase of 5.3% from $40.9 in 2024. For the quarter ending Mar 31, 2026, the EPS was $6.99, showing a 7.8% decrease from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $42.56. In 2024, the annual EPS was $40.9, showing an increase of 10.4% from 2023.

Over the last 12 months, Regeneron Pharmaceuticals has registered an EPS growth of -7.8% (YoY, quarterly). Over a three-year span, the company had an average EPS growth of 2.1% per year. Over the last 5 years, the company had an average EPS growth rate of 5.7%. When measured over a ten-year period, REGN's average EPS growth rate was 21.4%.